Work

A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in Combination with Daratumumab As a Salvage Regimen for Multiple Myeloma

Year: 2019

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2019-122494

Authors: Nina D. Shah, Cameron J. Turtle, Andrew J. Cowan, Julio C. Chavez, Lihua E Budde, Mario Q. Marcondes, Zachary Lee, Wei Lin, Jonathan Zalevsky, Mary Tagliaferri, Krina K. Patel

Institutions: University of California, San Francisco, Fred Hutch Cancer Center, University of Washington, Moffitt Cancer Center, City Of Hope National Medical Center, Nektar Therapeutics (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2986436720

Cites:

Cited by: 1

Related to: 10